Rufinamide in children and adults in routine clinical practice.

OBJECTIVE: To explore the long-term effectiveness of rufinamide in managing Lennox-Gastaut Syndrome (LGS), other epileptic encephalopathies, and intractable focal epilepsies in adults and children in routine clinical practice. METHODS: A multicentre, retrospective chart review of patients prescribed adjunctive rufinamide at seven Spanish epilepsy centres, with assessments at six and 12 months. RESULTS: We evaluated data from 58 patients (40 male, age range 7-57 years), 25 of whom were diagnosed with LGS, 12 with other epileptic encephalopathies and 21 of whom were diagnosed with focal epilepsies, mainly frontal lobe. The mean daily rufinamide dose was 32.0 mg/kg (range 12.5-66.7 mg/kg) in children and 24.7 mg/kg (range 5.0-47.0 mg/kg) in adults, and the most commonly used concomitant antiepileptic drugs were levetiracetam and valproate. Rufinamide was discontinued in 25 patients (43.1%) during the 1-year follow-up, and the most common reason was lack of effectiveness (n = 12, 20.7% of total). The frequency of generalized tonic-clonic seizures was significantly reduced from baseline at 6 and 12 months (P = 0.001), both in patients with generalized epilepsies and in patients with focal epilepsies. Significant seizure frequency reduction from baseline was observed at 12 months (P = 0.01) for tonic/atonic seizures and at 6 months (P = 0.001) for focal seizures. Side effects were reported in 21 patients (36.2%): nausea, vomiting and weight loss were most frequent. CONCLUSIONS: Rufinamide was well tolerated and was effective in reducing frequency of generalized tonic-clonic, tonic/atonic and focal seizures in both children and adults with severe refractory epilepsies, primarily LGS.

EEG extreme delta brush: An ictal pattern in patients with anti-NMDA receptor encephalitis.

INTRODUCTION: The anti-NMDA receptor (NMDAr) encephalitis-associated syndrome includes neuropsychiatric symptoms, impaired consciousness, seizures, autonomic instability, and hypoventilation. The electroencephalographic (EEG) activity throughout the course of the disease has still not been well documented. We reviewed electroclinical data of patients with NMDAr encephalitis to characterize their EEG and its clinical correlation. MATERIAL AND METHODS: We retrospectively identified 16 patients with NMDAr encephalitis from 8 Spanish medical centers, 15 of whom underwent video-EEG in the acute phase. RESULTS: In 15 patients (11 females, median age: 37.4, range: 14-87 years), seizures occurred in 9 (60%) and status epilepticus (SE) in 5 (33.3%). Magnetic resonance imaging (MRI) was abnormal in 10 (66.6%), and CSF (cerebrospinal fluid) was normal in 3 and abnormal in 12, with positive PCR (polymerase chain reaction) for Mycoplasma pneumoniae (1/15) and herpes simple virus (1/15). An ovarian teratoma was found in 1 patient and other malignancies (small cell lung carcinoma) in 1 patient. The EEG was abnormal in the acute phase in 14/15 (93.3%). Extreme delta brush (EDB) was observed in 5 (33.3%), and the presence of EDB was associated with SE in all cases. Rhythmic delta activity without EDB was observed in 5 (33.3%), while excessive beta activity was present in 4 (26.6%). Extreme delta brush can follow a pattern of well-characterized electroclinical seizures. CONCLUSIONS: Almost invariably, patients with NMDAr encephalitis had abnormal EEG. The presence of EDB, which can follow a pattern of well-characterized electroclinical seizures, in our patients was associated with seizures and SE. These findings suggest that EDB could be an evolutive pattern of an SE in NMDAr encephalitis. This article is part of a Special Issue entitled "Status Epilepticus".

Emergency perception and other variables associated with extra-hospital delay in stroke patients in the Maresme region (Spain).

Delay in arrival to the emergency room (ER) may negatively influence outcome of stroke patients. We aim to analyze factors that influence extra-hospital delay in stroke patients. Two hundred and ninety-two consecutive stroke patients admitted in the ER were prospectively studied. Analysis was made to identify variables associated with <1- and <3 h delays from onset. About 18.8% of patients arrived before 1 h and 57.5% before 3 h. Factors independently associated with <3 h delay were decision to go immediately to ER (OR = 8.17; 95% IC = 4.47-18.8), ambulance transportation (OR = 2.35; 1.36-4.05) and total anterior circulation syndrome (TACS) (OR = 3.74; 1.51-9.24). History of >1 vascular risk factor was associated with a greater delay (OR = 0.47; 0.26-0.86). Factors associated with a <1 h delay were: (i) immediate decision to attend the ER (OR = 3.55; 1.85-6.81), (ii) stroke on Sunday (OR = 3.46; 1.56-7.66), (iii) aphasia (OR = 2.41; 1.23-4.74), (iv) absence of stairs at home (OR = 0.37; 0.17-0.81) and (v) absence of diabetes mellitus (OR = 0.42; 0.20-0.88). In our area, nearly 60% of stroke patients arrive to ER before 3 h from onset. Immediate decision to attend the ER has the strongest association with a short delay. Patients with TACS arrived mainly before 3 h and those with isolated aphasia arrived before 1 h. Patients with vascular risk factors attended the hospital later. Ambulance transportation is associated with <3 h delay, but not with <1 h.

Anterior choroidal artery infarction: a clinical, etiologic and prognostic study.

OBJECTIVES: To analyze the clinical, etiologic and prognostic profile of anterior choroidal artery (AChA) infarcts. METHODS: 42 consecutive patients with AChA infarction were included. Symptoms, etiology and scores on neurological and functional scales were analyzed on admission, discharge and at 3-month follow-up. A comparative study was performed between deep (n = 23) and deep + superficial (n = 19) infarcts. RESULTS: Lacunar syndrome was present in 83.3% of patients. Etiology was large-vessel disease in 38.1% and cryptogenic in 38.1%. Ten patients had a National Institute of Health Stroke Scale score >7 on admission. At discharge, 45.3% had an modified Rankin Scale >2 (35.7% after 3 months). Infarcts involving superficial territory were more severe at admission (P = 0.034) and were associated with a worse functional status at discharge (P = 0.0008). CONCLUSION: AChA infarcts usually present with lacunar syndrome, although they are often not lacunar infarcts. At discharge, almost half of the patients are dependent in their activities of daily living, and most remain so at 3-month follow-up. Infarcts involving superficial territory are associated with worse prognosis.

Eficacia y tolerabilidad del levetiracetam en pacientes con temblor esencial: datos de un ensayo abierto de 11 semanas de seguimiento / Effectiveness and safety of levetiracetam in patients with essential tremor data from an open 11-week follow-up trial

Introducción. Es bien conocida la relativamente alta proporción de pacientes con temblor esencial refractarios a varios fármacos conocidos en la actualidad para su tratamiento. Objetivo. Evaluar la eficacia y la tolerabilidad del levetiracetam (LEV) en pacientes que hubieran mostrado respuesta escasa o nula o efectos secundarios intolerables en tratamiento con betabloqueadores o primidona, o presentasen contraindicaciones para el inicio de estos tratamientos. Pacientes y métodos. Llevamos a cabo un estudio piloto, abierto, de 11 semanas de duración en pacientes con las características descritas previamente. Las medidas principales de respuesta se basaron en la escala de temblor de Fahn, Tolosa y Marín (FTM), variables acelerométricas y efectos adversos. La dosis máxima de LEV fue de 3.000 mg, a la que llegaron los pacientes que no presentaron beneficio con dosis inferiores, tras una semana de tratamiento con 1.000 mg y cuatro semanas de tratamiento con 2.000 mg. Resultados. La muestra consistió en 14 pacientes con temblor esencial, con una media de edad de 70,08 (7,99) años y una mediana de 11,5 años de clínica. Aunque se observaron pequeños descensos en la escala de FTM y en la amplitud del temblor al final del estudio, ninguna de las diferencias observadas fue significativa. Seis pacientes abandonaron el estudio por falta de eficacia o efectos adversos. Conclusión. El LEV no produjo modificaciones estadísticamente significativas en ninguna de las variables controladas en este perfil de pacientes

Introduction. It is a well-known fact that a relatively high proportion of patients with essential tremor are resistant to a number of pharmaceuticals currently used to treat the condition. Aim. To assess the effectiveness and safety of levetiracetam (LEV) in patients who displayed little or no response or intolerable side effects under treatment with beta blockers or primidone, or who presented contraindications against beginning such treatments. Patients and methods. We conducted an open 11-week pilot study in patients with the characteristics described above. The main response measurements were based on the Fahn-Tolosa-Marín (FTM) tremor rating scale, accelerometric variables and side effects. The maximum dose of LEV was 3000 mg, which was reached by patients who did not benefit from lower doses, after one week’s treatment with 1000 mg and four weeks’ treatment with 2000 mg. Results. The sample consisted of 14 patients with essential tremor, with a mean age of 70.08 (7.99) years and an average clinical history of 11.5 years. Although by the end of the study small decreases were observed on the FTM rating scale and in the amplitude of the tremor, none of the differences were significant. Six patients dropped out of the study because of a lack of effectiveness or to side effects. Conclusion. LEV did not produce any statistically significant modifications in any of the variables that were monitored in this group of patients

[Effectiveness and safety of levetiracetam in patients with essential tremor: data from an open 11-week follow-up trial]. / Eficacia y tolerabilidad del levetiracetam en pacientes con temblor esencial: datos de un ensayo abierto de 11 semanas de seguimiento.

INTRODUCTION: It is a well-known fact that a relatively high proportion of patients with essential tremor are resistant to a number of pharmaceuticals currently used to treat the condition. AIM: To assess the effectiveness and safety of levetiracetam (LEV) in patients who displayed little or no response or intolerable side effects under treatment with beta blockers or primidone, or who presented contraindications against beginning such treatments. PATIENTS AND METHODS: We conducted an open 11-week pilot study in patients with the characteristics described above. The main response measurements were based on the Fahn-Tolosa-Marin (FTM) tremor rating scale, accelerometric variables and side effects. The maximum dose of LEV was 3000 mg, which was reached by patients who did not benefit from lower doses, after one week's treatment with 1000 mg and four weeks' treatment with 2000 mg. RESULTS. The sample consisted of 14 patients with essential tremor, with a mean age of 70.08 (7.99) years and an average clinical history of 11.5 years. Although by the end of the study small decreases were observed on the FTM rating scale and in the amplitude of the tremor, none of the differences were significant. Six patients dropped out of the study because of a lack of effectiveness or to side effects. CONCLUSION: LEV did not produce any statistically significant modifications in any of the variables that were monitored in this group of patients.

Cortical laminar necrosis related to prolonged focal status epilepticus.

Cortical laminar necrosis (CLN) is radiologically defined as high intensity cortical lesions on T1 weighted MRI images following a gyral distribution. Histopathologically, CLN is characterised by pannecrosis of the cortex involving neurones, glial cells, and blood vessels. It has been reported to be associated with hypoxia, metabolic disturbances, drugs, and infections. We present two patients who developed CLN and permanent neurological deficits after prolonged and repeated focal status epilepticus. The possible mechanisms leading to CLN in these patients are discussed, together with the implications of prompt and aggressive treatment in similar cases.

[Clinical utility of outpatient videoelectroencephalogram monitoring]. / Utilidad clínica del videoelectroencefalograma en régimen ambulatorio.

OBJECTIVE: To analyze the utility of outpatient videoelectroencephalogram (VEEG) in a general neurology department to detect an ictal event. PATIENTS AND METHODS: One hundred and five patients with ictal phenomenology of unknown etiology, suspicion of pseudoseizures, refractory epilepsy with very frequent seizures, underwent outpatient VEEG monitoring from 30 minutes to five hours of duration, between June 1, 1999 and June 30, 2003. Patient medication was not modified to perform the recording. RESULTS: Among the 105 outpatient VEEG monitoring, 33 clinical pathologic events were identified; these comprised 14 epileptic seizures, 12 pseudoseizures, four syncopes, and three non epileptic abnormal movements. Outpatient VEEG monitoring duration was as follows: 30 minutes in 12 patients, between 30 minutes and two hours in another 12, and more than two hours in 9. In 19 patients, the VEEG recording allowed a definitive diagnosis; in one case, it changed the epileptic seizure type, and in 11 patients, it helped to better characterize the epileptic seizure type. CONCLUSION: Although the percentage of pathologic events during an outpatient VEEG monitoring of 30 minutes to five hours of duration is low, its clinical repercussion is very important and the added cost is low.

Utilidad clínica del videoelectroencefalograma en régimen ambulatorio / Clinical utility of outpatient videoelectroencephalogram monitoring

Objetivo. Analizar la utilidad de los registros por video-electroencefalograma (VEEG) en régimen ambulatorio realizados en un servicio de neurología general para la detección de un episodio crítico. Pacientes y métodos. Desde el 1 de junio de 1999 hasta el 1 de junio de 2003 realizamos 105 exploraciones por VEEG, de 30 minutos a 5 horas de duración, en pacientes con crisis de etiología no aclarada, ante la sospecha de pseudocrisis o en presencia de una epilepsia farmacorresistente y crisis muy frecuentes. No modificamos la medicación del paciente para realizar la exploración. Resultados. En 33 pacientes se registraron eventos clínicos patológicos; en 14 se trató de crisis epilépticas, en 12 de pseudos crisis, en 4 de síncopes y en 3 de movimientos anormales no epilépticos. La duración del registro fue de 30 minutos en 12, de entre 30 minutos y 2 horas en 12 y de más de 2 horas en 9 pacientes. En 18 pacientes el VEEG fue la exploración diagnóstica. En un caso cambió el diagnóstico del tipo de crisis epiléptica que sufría el paciente, y en 11 pacientes nos ayudó a caracterizar sus crisis epilépticas. Conclusión. Si bien el porcentaje de registro de eventos patológicos durante un estudio por VEEG ambulatorio de 30 minutos a 5 horas de duración es bajo, su repercusión clínica es muy alta y el coste añadido, escaso

Objective. To analyze the utility of outpatient videoelectroencephalogram (VEEG) in a general neurology department to detect an ictal event. Patients and methods. One hundred and five patients with ictal phenomenology of unknown etiology, suspicion of pseudoseizures, refractory epilepsy with very frequent seizures, underwent outpatient VEEG monitoring from 30 minutes to five hours of duration, between June 1, 1999 and June 30, 2003. Patient medication was not modified to perform the recording. Results. Among the 105 outpatient VEEG monitoring, 33 clinical pathologic events were identified; these comprised 14 epileptic seizures, 12 pseudoseizures, four syncopes, and three non epileptic abnormal movements. Outpatient VEEG monitoring duration was as follows: 30 minutes in 12 patients, between 30 minutes and two hours in another 12, and more than two hours in 9. In 19 patients, the VEEG recording allowed a definitive diagnosis; in one case, it changed the epileptic seizure type, and in 11 patients, it helped to better characterize the epileptic seizure type. Conclusion. Although the percentage of pathologic events during an outpatient VEEG monitoring of 30 minutes to five hours of duration is low, its clinical repercussion is very important and the added cost is low

[Hereditary neuropathy with liability to pressure palsies: study of six Spanish families]. / Neuropathies héréditaires sensibles à la pression: étude de six familles espagnoles.

Hereditary neuropathy with liability to pressure palsies (HNPP) is an autosomal dominant inherited demyelinating neuropathy typically characterized by recurrent episodes of acute painless peripheral nerve palsies often preceded by minor trauma or compression at entrapment sites. However, less classical phenotypes have been reported. A 1.5 Mb deletion in chromosome 17 p11.2 has been shown to be the genetic basis of the disease in the majority of HNPP patients. The few families without this deletion harbored a mutation in the PMP22 gene. We performed a clinical, neurophysiological and molecular genetic study of 6 Spanish HNPP families. Five families (22 individuals) showed the classical chromosome 17 p11.2 deletion and one family (3 individuals) had a novel 3'splice-site mutation in PMP22. Neurophysiological abnormalities were detected in all symptomatic (n=21) and asymptomatic (n=4) deletion or mutation carriers, even in childhood. In addition to the typical presentation we observed other phenotypes: recurrent focal short-term sensory symptoms, a progressive mononeuropathy, a Charcot-Marie-Tooth (CMT) disease-like chronic progressive polyneuropathy, a chronic sensory polyneuropathy and a chronic inflammatory demyelinating polyneuropathy. We report new or very rare phenotypesThese atypical clinical aspects and intrafamilial heterogeneity are present in families with the HNPP deletion as well as in the family with the PMP22 mutation. However, the CMT disease-like chronic polyneuropathy was more common in the PMP22 mutation family. Intrafamilial heterogeneity also seemed to be more pronounced in this kinship. Patients in this family had a mild chronic motor and sensory polyneuropathy neurophysiologically characterized by delayed distal latencies, reduced nerve conduction velocities (NCV) within the demyelinating range, mildly decreased amplitudes of motor and sensory evoked potentials and absence of conduction blocks. In contrast, patients with the common HNPP deletion, regardless of their phenotype, had a diffuse increase in distal motor latencies contrasting with moderately reduced motor NCVs, preserved sensory nerve action potentials, slowing of NCVs at the common entrapment sites and occasionally conduction blocks. In this study we confirm the clinical and molecular heterogeneity of HNPP, emphasizing the need for a mutation analysis of the PMP22 gene when the common 17p11.2 deletion is not found in clinically suspected HNPP patients. We conclude that the 3'splice-site mutation in PMP22 and the common HNPP deletion have largely the same functional consequences although some clinical and neurophysiological differences were observed.

[Validation of transcranial Doppler in Mataro, Barcelona]. / Validación del Doppler transcraneal en Mataró, Barcelona.

INTRODUCTION: Transcranial Doppler (TCD) is a new technique which is becoming increasingly used in neurology and is highly dependent on the user. OBJECTIVE: To evaluate the reliability of TCD in our hospital. PATIENTS AND METHODS: During a five month period, all patients who had a cerebral angiogram done, also had DTC within 24 hours. The TCD was reported on before the result of the angiogram was known. Subsequent analysis of the comparison of the results was done by a person who had not done the initial investigations. RESULTS: 49 persons were included in the study. The average time between the two investigations was 12.5 hours. In 5 patients the TCD was inconclusive due to a poor window. In 21 patients both tests were normal. Of the 14 patients in whom there were pathological findings on angiography, correct diagnosis was made on TCD in 12 cases, including those with stenosis of the anterior circulation. The two false negative findings of intracranial stenosis were in a vertebral artery and a posterior cerebral artery. The remaining seven cases were of patients in whom only one investigation showed signs of distal vasculopathy. CONCLUSION: The index of false positives of DTC showing intracranial stenosis was 0. All intracranial stenoses of the anterior circulation were correctly diagnosed.

[Partial benign crises in adolescence]. / Crisis parciales benignas en la adolescencia.

The aim of this paper is to present the case of teenage patient with partial seizures fulfilling the criteria of benign partial seizures of adolescence. A 16-year-old male patient had two seizures with a sensory-motor "march" that evolved into a secondarily generalized tonic-clonic seizure on the same day. Several weeks before this event he had had several simple partial sensory seizures. The patient had no previous history of seizures and there was no family history of epilepsy. The neurological examination, EEG and magnetic resonance imaging were normal. The patient was treated with antiepileptic monotherapy during two years. The treatment was gradually tapered and withdrawn over the following six months. He has had no recurrences during the five years of follow-up. The early diagnosis of this entity has the significant prognostic and therapeutic repercussions.

Crisis parciales benignas en la adolescencia / Partial benign crises in adolescence

El objetivo de este trabajo es aportar el caso de un varón de 16 años con crisis parciales que reúne los criterios del síndrome de la epilepsia parcial benigna de la adolescencia. Se trata de un paciente que presentó, en el mismo día, dos crisis parciales con una evolución sensitivomotora y generalización tónico-clónica secundaria. Había sufrido múltiples crisis parciales sensitivas en las semanas previas. No existían antecedentes personales ni familiares de epilepsia. La exploración neurológica, el electroencefalograma y la resonancia magnética cerebral fueron normales. Se realizó tratamiento en monoterapia durante dos años, que se suprimió de forma progresiva en 6 meses. Tras 5 años de evolución no se han producido recurrencias. El diagnóstico temprano de este síndrome tiene importantes repercusiones pronósticas y terapéuticas. (AU)

Tratamiento profiláctico de la migraña con flunaricina:¿5 o 10 mg? / Prophyllactic treatment of migraine with flunarizine: 5 mg or 10 mg?

No disponible

[Analysis of cost minimization of monotherapy antiepileptic treatment in patients with recent diagnosed epilepsy : the situation in Spain]. / Análisis de coste-minimización del tratamiento antiepiléptico en monoterapia en pacientes con epilepsia de reciente diagnóstico: situación en España.

OBJECTIVE: To analyze the cost of monotherapeutic treatment of patients with newly diagnosed epilepsy. PATIENTS AND METHODS: We analysed the cost of treatment with lamotrigine (LTG), carbamazepine (CBZ), phenytoin (PHT) and valproic acid (VPA) using published data regarding the efficacy and tolerability of comparative clinical trials of monotherapy. We established a model of treatment for newly diagnosed patients during the first 12 months after diagnosis. A panel of doctors reached a consensus on the use of resources, costs and model of treatment in Spain. We made a cost minimization analysis for economic assessment of the data based on the fact that randomized trials indicated that CBZ, LTG, PHT and VPA ware of similar efficacy. Analysis was done as 'intention to treat'. Only direct medical costs were considered. RESULTS: In Spain treatment with LTG is twice or three times as expensive as treatment with the other drugs. Sensitivity analysis showed that variations in the interval of use of resources and of costs (defined by the panel of doctors) did not significantly alter the results. CONCLUSIONS: Treatment with LTG is more expensive than treatment with the classical drugs. In view of the methodological limitations of this study, further analysis is necessary, particularly of the methodology of cost-benefit, to evaluate the economic impact of the new antiepileptic drugs and determine whether their use is justified as drugs of first choice.

Migraine without aura and migrainous disorder in children; International Headache Society (IHS) and revised IHS criteria.

The widely used criteria of the IHS to define migraine without aura in children are highly specific but show poor sensitivity, with a large percentage of headaches being classified as migrainous disorder (MD). The objective of this study was to assess how many headache patients in a series of children met the diagnostic criteria of the IHS for migraine without aura or MD and to determine the changes required to convert the greatest number of MD into migraine without aura, without affecting classification of the remaining headache types. A prospective study was undertaken of 131 patients under 15 years old referred to our centre for headache. Patients were classified according to the IHS criteria and according to a modification of these criteria consisting of: (1) reduction of minimum time required for classification into migraine without aura from 2 h to 1 h; (2) acceptance of bifrontal location in addition to hemicranial; (3) acceptance of either phonophobia or photophobia as valid criteria instead of requiring presence of both. Using the IHS criteria, 51 (39%) children were diagnosed as having migraine without aura and 26 (20%) as having MD. According to our revised IHS criteria, 68 (52%) were diagnosed as migraine without aura and nine (7%) as MD. When the three modified criteria were applied, three tension headaches and one unclassifiable headache changed category. When only reduced duration and bifrontal location were applied, none of the headaches other than MD changed category. Application of two modifications to the IHS criteria--reduction in duration of headache to 1 h and acceptance of bifrontal location--increased sensitivity without reducing specificity in classifying migraine without aura in children.

Análisis de coste-minimización del tratamiento antiepilépticoen monoterapia en pacientes con epilepsia de reciente diagnóstico:situación en España / Cost minimization analysis of monotherapy for antiepileptic treatment in patients with newly diagnosed epilepsy: the position in Spain

Objetivo. Analizar el coste del tratamiento en monoterapia de los pacientes con epilepsia de reciente comienzo. Pacientes y métodos. Se analizó el coste del tratamiento con lamotrigina (LTG), carbamacepina (CBZ), fenitoína (PHT) y ácido valproico (VPA) utilizando datos publicados sobre eficacia y tolerabilidad de los ensayos clínicos comparativos en monoterapia. Se estableció un modelo de tratamiento de pacientes con epilepsia de reciente comienzo durante los primeros 12 meses tras su diagnóstico. Un panel de médicos consensuó el uso de recursos, costes y el modelo de tratamiento en nuestro país. Se llevó a cabo un análisis de coste-minimización para evaluar económicamente los datos, basado en que los ensayos aleatorizados indicaban que CBZ, LTG, PHT y VPA eran de eficacia similar. El análisis se realizó como `intención de tratar'. Únicamente se consideraron los costes médicos directos. Resultados. En nuestro país, el tratamiento con LTG es entre dos y tres veces más costoso que con las otras medicaciones. Un análisis de sensibilidad demostró que variaciones en el intervalo de uso de recursos y de costes (definido por el panel de médicos) no alteraban de forma significativa los resultados. Conclusiones. El tratamiento con LTG es más costoso que el tratamiento con fármacos clásicos. Dadas las limitaciones metodológicas del actual estudio, se precisan nuevos análisis, especialmente con metodología de coste-beneficio, para valorar el impacto económico de los nuevos antiepilépticos y determinar si está justificada su utilización como fármaco de primera elección (AU)

Dystonia in a patient treated with propranolol and gabapentin.

We present a 68-year-old patient with essential tremor who was treated with propranolol hydrochloride (80 mg daily) and gabapentin (900 mg daily) after a history of mild success of gabapentin alone in relieving his symptoms. The patient had several daily episodes of paroxysmal dystonic movements in both hands. After reducing the propranolol dose to 40 mg daily, the dystonic movements resolved. This case suggests a synergistic effect between propranolol and gabapentin.